SCHEMBL19463255

SCHEMBL19463255

Cc1nn2c(C(C)C)c(C(=O)N[C@H]3CCc4ccccc43)cnc2c1Br

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 1/20 0.55
▸ SPR P35270 2/20 0.45
▸ TAS1R3 Q7RTX0 6/20 0.44
▸ TAS1R1 Q7RTX1 6/20 0.44
▸ TAS1R2 Q8TE23 6/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ PDE10A Q9Y233 2/20 0.42
▸ POLB P06746 2/20 0.42
▸ HPGDS O60760 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.41
▸ RECQL P46063 1/20 0.40
▸ CNR1 P21554 1/20 0.40
▸ CNR2 P34972 1/20 0.40
▸ KCNA5 P22460 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20768127 1.00 PDE2A (0.55) PDE2ASPRTAS1R3TAS1R1TAS1R2
SCHEMBL19463266 0.95 TAS1R3 (0.52) PDE2ASPRTAS1R3TAS1R1TAS1R2
SCHEMBL19463267 0.95 TAS1R3 (0.52) PDE2ASPRTAS1R3TAS1R1TAS1R2
SCHEMBL19464236 0.90 PDE2A (0.52) PDE2ASPRTAS1R3TAS1R1TAS1R2
SCHEMBL20768144 0.90 PDE2A (0.52) PDE2ASPRTAS1R3TAS1R1TAS1R2
SCHEMBL20768138 0.89 PDE2A (0.50) PDE2ASPRTAS1R3TAS1R1TAS1R2
SCHEMBL19464223 0.89 PDE2A (0.50) PDE2ASPRTAS1R3TAS1R1TAS1R2
SCHEMBL20768137 0.88 PDE2A (0.57) PDE2ASPRTAS1R3TAS1R1TAS1R2
SCHEMBL19492653 0.88 PDE2A (0.57) PDE2ASPRTAS1R3TAS1R1TAS1R2
SCHEMBL19464218 0.86 BRD4 (0.40) PDE2ATAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024213752-A1 LONG-TERM PREVENTION AND/OR TREATMENT OF A DISEASE BY SLO-1 INHIBITORS ELANCO ANIMAL HEALTH GMBH (DE) 2024-10-17 — — WO disclosed
EP-3442974-B1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2023-06-07 — — EP disclosed
CN-109071545-B Novel pyrazolopyrimidine derivatives 拜耳动物保健有限责任公司 2021-08-03 — — CN disclosed
US-11001590-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-05-11 — — US disclosed
US-11001590-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-05-11 — — US disclosed
US-10934301-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-03-02 — — US disclosed
US-10934301-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-03-02 — — US disclosed
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-09-24 — — US disclosed
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-09-24 — — US disclosed
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-07-30 — — US disclosed
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-07-30 — — US disclosed
US-10604525-B2 Pyrazolopyrimidine derivatives BAYAL ANIMAL HEALTH GMBH (DE) 2020-03-31 — — US disclosed
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2019-03-07 — — US disclosed
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2019-03-07 — — US disclosed
EP-3442974-A1 PYRAZOLOPYRIMIDINE DERIVATIVES Bayer Animal Health GmbH (DE) 2019-02-20 — — EP disclosed
WO-2017178416-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2017-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604525-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 PDE2A 816/4885SPR 1441/4885TAS1R3 2798/4885
US-11001590-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 PDE2A 785/4885SPR 1409/4885TAS1R3 2894/4885
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 PDE2A 816/4885SPR 1441/4885TAS1R3 2798/4885
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 PDE2A 785/4885SPR 1409/4885TAS1R3 2894/4885
US-10934301-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 PDE2A 785/4885SPR 1409/4885TAS1R3 2894/4885
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 PDE2A 684/4885SPR 1515/4885TAS1R3 2879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback